Clinical Trials Logo

Brutons Tyrosine Kinase clinical trials

View clinical trials related to Brutons Tyrosine Kinase.

Filter by:
  • None
  • Page 1

NCT ID: NCT03642236 Enrolling by invitation - Clinical trials for Acute Myeloid Leukemia

Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML

Start date: August 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Clinical efficacy of FLT3 inhibitors combining with chemotherapy is usually transient and followed by emergence of drug-resistance in FLT3-ITD mutant AML. BTK is reported to be a therapeutic target in this subtype leukemia. Our previous study showed inhibition of BTK onvercome drug-resistance to FLT3 inhibitors/chemotherapy in refractory/relapsed FLT3 mutant AML. In this prospective randomized controlled study, the efficacy and safety of combination of BTK inhibitor with chemotherapy with/without FLT3 inhibitor in refractory/relapsed FLT3 mutant AML are evaluated.